Monte Rosa Therapeutics, Inc. (GLUE) — Stock Score Summary

Monte Rosa Therapeutics, Inc. (GLUE) has a MoatMap StockRank of 35/100 based on Quality (33/100), Value (37/100), and Momentum (53/100) factor scores. The current signal is HOLD. Monte Rosa Therapeutics is a clinical-stage biotech company. It lacks the predictable cash flows, high ROIC, and established commercial products required by our quality-focused investment lenses.

Monte Rosa Therapeutics is an early-stage biotechnology company developing novel precision medicines that leverage its proprietary molecular glue degrader platform to target and eliminate disease-causing proteins. Its competitive edge lies in this innovative platform, which enables the degradation of historically undruggable targets, opening new therapeutic avenues. The company focuses on developing treatments for difficult-to-treat cancers and other intractable diseases.

Key Financial Metrics

Price$17.59
Market Cap$1.6B
P/E (Forward)-10.58
Price/Book3.10
Return on Equity-32.6%
Return on Invested Capital-14.1%
Debt/Equity7.49
Gross Margin-238.5%
Operating Margin-1188.5%
Revenue Growth-95.0%
Free Cash Flow$-77M

Monte Rosa Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Monte Rosa Therapeutics, Inc.’s (GLUE) StockRank?
MoatMap’s StockRank for Monte Rosa Therapeutics, Inc. (GLUE) is 35/100, with a Hold signal. It is a composite of Quality (33), Value (37), and Momentum (53) factor ranks across MoatMap’s 19,000+ stock universe.
Does Monte Rosa Therapeutics, Inc. have an economic moat?
Monte Rosa Therapeutics, Inc. (GLUE) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Monte Rosa Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Monte Rosa Therapeutics, Inc. (GLUE) is Hold, based on a StockRank of 35/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Monte Rosa Therapeutics, Inc. in?
Monte Rosa Therapeutics, Inc. (GLUE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksGLUE deep dive reportAI ChampionsHow we score stocksSense-check another stock